Lisata Therapeutics (LSTA) is entering a pivotal, data-rich period with several clinical milestones on the horizon. The company has strengthened its position through a global license agreement with Catalent to integrate certepetide into the SMARTag ADC platform and a strategic alliance with GATC Health to leverage AI-powered drug discovery. With multiple ongoing trials showcasing certepetide's potential to boost the effectiveness of chemotherapy, immunotherapy, and ADCs, and a cash runway secured into early 2027 with no debt, Lisata is well-positioned for meaningful progress in the near term.
Company Overview
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com